Fonte: Hormone research in paediatrics. Nome do evento: Joint meeting of paediatric endocrinology. Unidade: FM
Assuntos: HIPERPLASIA SUPRARRENAL CONGÊNITA, HORMÔNIOS GLICOCORTICOIDES, CRIANÇAS, ADULTOS
ABNT
DANIEL, Eleni e MENDONÇA, Berenice Bilharinho de e BACHEGA, Tânia Aparecida Sartori Sanchez. Defining the dose, type and timing of glucocorticoid and mineralocorticoid replacement in 256 children and adults with congenital adrenal hyperplasia (CAH) in the I-CAH registry. Hormone research in paediatrics. Basel: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 02 nov. 2024. , 2017APA
Daniel, E., Mendonça, B. B. de, & Bachega, T. A. S. S. (2017). Defining the dose, type and timing of glucocorticoid and mineralocorticoid replacement in 256 children and adults with congenital adrenal hyperplasia (CAH) in the I-CAH registry. Hormone research in paediatrics. Basel: Faculdade de Medicina, Universidade de São Paulo.NLM
Daniel E, Mendonça BB de, Bachega TASS. Defining the dose, type and timing of glucocorticoid and mineralocorticoid replacement in 256 children and adults with congenital adrenal hyperplasia (CAH) in the I-CAH registry. Hormone research in paediatrics. 2017 ; 88 358. res. P2-1503.[citado 2024 nov. 02 ]Vancouver
Daniel E, Mendonça BB de, Bachega TASS. Defining the dose, type and timing of glucocorticoid and mineralocorticoid replacement in 256 children and adults with congenital adrenal hyperplasia (CAH) in the I-CAH registry. Hormone research in paediatrics. 2017 ; 88 358. res. P2-1503.[citado 2024 nov. 02 ]